Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, 1500 East Medical Center Drive, SPC 5362, Ann Arbor, MI 48109, USA.
Gastroenterol Clin North Am. 2011 Mar;40(1):163-82. doi: 10.1016/j.gtc.2010.12.008.
Gut-acting therapies are common therapies for irritable bowel syndrome (IBS). Most of these peripheral acting agents are primarily targeted at individual symptoms. The evidence supporting the use of these agents in IBS is largely anecdotal. Serotonergic agents and the chloride channel activator lubiprostone have shown efficacy in treating symptoms of IBS. The clinical evidence supporting the use of these agents is based on data from high-quality clinical trials. The use of serotonergic agents for IBS in the United States is limited to the 5-hydroxytryptamine-3 antagonist alosetron in the treatment of women with severe IBS with diarrhea refractory to traditional therapy.
肠道作用治疗药物是肠易激综合征（IBS）的常用治疗药物。这些外周作用药物大多主要针对个别症状。支持这些药物在 IBS 中应用的证据主要是轶事证据。血清素能药物和氯离子通道激活剂鲁比前列酮已被证明可有效治疗 IBS 症状。支持这些药物应用的临床证据基于高质量临床试验的数据。在美国，肠易激综合征中使用血清素能药物仅限于治疗对传统疗法难治性严重腹泻型 IBS 的女性的 5-羟色胺-3 拮抗剂阿洛司琼。
